{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:27:26Z","timestamp":1787624846748,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["ZE 432\/10-1"],"award-info":[{"award-number":["ZE 432\/10-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU344\/417911533"],"award-info":[{"award-number":["CRU344\/417911533"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU344\/417911533"],"award-info":[{"award-number":["CRU344\/417911533"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["ForTra (PrickMe)"],"award-info":[{"award-number":["ForTra (PrickMe)"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Primary myelofibrosis (PMF) is a clonal blood disorder characterized by mutually exclusive driver mutations in <jats:italic>JAK2<\/jats:italic>, <jats:italic>CALR<\/jats:italic>, or <jats:italic>MPL<\/jats:italic> genes. So far, it is largely unclear if the driver mutations have a specific impact on DNA methylation (DNAm) profiles and how epigenetic alterations in PMF are related to other myeloid malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>When we compared DNAm profiles from PMF patients we found very similar epigenetic modifications in <jats:italic>JAK2<\/jats:italic> and <jats:italic>CALR<\/jats:italic> mutated cases, whereas <jats:italic>MPL<\/jats:italic> mutations displayed less pronounced and distinct patterns. Furthermore, induced pluripotent stem cell (iPSC) models with <jats:italic>JAK2<\/jats:italic> mutations indicated only a moderate association with PMF-related epigenetic changes, suggesting that these alterations may not be directly driven by the mutations themselves. Additionally, PMF-associated epigenetic changes showed minimal correlation with allele burden and seemed to be largely influenced by shifts in the cellular composition. PMF DNAm profiles compared with those from other myeloid malignancies\u2014such as acute myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic syndrome\u2014showed numerous overlapping changes, making it difficult to distinguish PMF based on individual CpGs. However, a PMF score created by combining five CpGs was able to discern PMF from other diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings demonstrate that PMF driver mutations do not directly evoke epigenetic changes. While PMF shares epigenetic alterations with other myeloid malignancies, DNA methylation patterns can distinguish between PMF and related diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13148-025-01877-1","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T07:39:09Z","timestamp":1746257949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies"],"prefix":"10.1186","volume":"17","author":[{"given":"Esra","family":"Dursun Torlak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithurithra","family":"Tharmapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kricheldorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Schifflers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Caduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"issue":"7","key":"1877_CR1","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"1877_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97\u2013105.","journal-title":"JAMA Oncol"},{"issue":"25","key":"1877_CR3","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med. 2013;369(25):2379\u201390.","journal-title":"New Engl J Med"},{"issue":"5","key":"1877_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tig.2015.03.002","volume":"31","author":"G Lev Maor","year":"2015","unstructured":"Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in splicing regulation. Trends Genet. 2015;31(5):274\u201380.","journal-title":"Trends Genet"},{"issue":"3","key":"1877_CR5","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-12-0735","volume":"73","author":"S Nischal","year":"2013","unstructured":"Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Can Res. 2013;73(3):1076\u201385.","journal-title":"Can Res"},{"issue":"9","key":"1877_CR6","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","volume":"98","author":"C P\u00e9rez","year":"2013","unstructured":"P\u00e9rez C, Pascual M, Mart\u00edn-Subero JI, Bellosillo B, Segura V, Delabesse E, et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2013;98(9):1414\u201320.","journal-title":"Haematologica"},{"key":"1877_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01010-y","author":"U Lehmann","year":"2021","unstructured":"Lehmann U, Stark H, Bartels S, Schlue J, B\u00fcsche G, Kreipe H. Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis. Clin Epigenetics. 2021. https:\/\/doi.org\/10.1186\/s13148-021-01010-y.","journal-title":"Clin Epigenetics"},{"key":"1877_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01342-6","author":"A Zhao","year":"2023","unstructured":"Zhao A, Zhou H, Yang J, Li M, Niu T. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduction Targeted Therapy. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01342-6.","journal-title":"Signal Transduction Targeted Therapy"},{"issue":"7943","key":"1877_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA methylation atlas of normal human cell types. Nature. 2023;613(7943):355\u201364.","journal-title":"Nature"},{"issue":"8","key":"1877_CR10","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41375-018-0125-x","volume":"32","author":"M Kirschner","year":"2018","unstructured":"Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, et al. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia. 2018;32(8):1762\u20137.","journal-title":"Leukemia"},{"key":"1877_CR11","doi-asserted-by":"publisher","first-page":"8489","DOI":"10.1038\/ncomms9489","volume":"6","author":"N Jung","year":"2015","unstructured":"Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat Commun. 2015;6:8489.","journal-title":"Nat Commun"},{"issue":"4","key":"1877_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","volume":"35","author":"S Adnan Awad","year":"2021","unstructured":"Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35(4):1087\u201399.","journal-title":"Leukemia"},{"issue":"2","key":"1877_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/leu.2013.338","volume":"28","author":"MA Dawson","year":"2014","unstructured":"Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014;28(2):311\u201320.","journal-title":"Leukemia"},{"issue":"5","key":"1877_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SCW, Ramakrishnan A, et al. Mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27(5):617\u201330.","journal-title":"Cancer Cell"},{"issue":"8","key":"1877_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ng.2696","volume":"45","author":"H Makishima","year":"2013","unstructured":"Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45(8):942\u20136.","journal-title":"Nat Genet"},{"issue":"2","key":"1877_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/onc.2010.409","volume":"30","author":"DD De Carvalho","year":"2011","unstructured":"De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene. 2011;30(2):223\u201333.","journal-title":"Oncogene"},{"issue":"8","key":"1877_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3324\/haematol.2018.204917","volume":"104","author":"N Martinez-Calle","year":"2019","unstructured":"Martinez-Calle N, Pascual M, Ordonez R, Eneriz ESJ, Kulis M, Miranda E, et al. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated. Haematologica. 2019;104(8):1572\u20139.","journal-title":"Haematologica"},{"key":"1877_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2022.106229","volume":"149","author":"M Gl\u00fcck","year":"2022","unstructured":"Gl\u00fcck M, Dally L, J\u00fccker M, Ehm P. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN). Int J Biochem Cell Biol. 2022;149: 106229.","journal-title":"Int J Biochem Cell Biol"},{"issue":"43","key":"1877_CR19","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1038\/onc.2010.303","volume":"29","author":"L Li","year":"2010","unstructured":"Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, et al. A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K\/AKT signaling. Oncogene. 2010;29(43):5785\u201395.","journal-title":"Oncogene"},{"issue":"20","key":"1877_CR20","doi-asserted-by":"publisher","first-page":"12380","DOI":"10.3390\/ijms232012380","volume":"23","author":"S Jayaprakash","year":"2022","unstructured":"Jayaprakash S, Hegde M, BharathwajChetty B, Girisa S, Alqahtani MS, Abbas M, et al. Unraveling the potential role of NEDD4-like E3 ligases in cancer. Int J Mol Sci. 2022;23(20):12380.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1877_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stemcr.2023.12.011","volume":"19","author":"N Flosdorf","year":"2024","unstructured":"Flosdorf N, B\u00f6hnke J, de Toledo MAS, Lutterbach N, Lerma VG, Grasshoff M, et al. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in\u00a0vitro bone marrow niche. Stem Cell Rep. 2024;19(2):224\u201338.","journal-title":"Stem Cell Rep"},{"key":"1877_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.667304","volume":"9","author":"T Satoh","year":"2021","unstructured":"Satoh T, Toledo MAS, Boehnke J, Olschok K, Flosdorf N, Gotz K, et al. Human DC3 antigen presenting dendritic cells from induced pluripotent stem cells. Front Cell Dev Biol. 2021;9: 667304.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1877_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.stemcr.2022.11.001","volume":"18","author":"M Schmidt","year":"2023","unstructured":"Schmidt M, Zeevaert K, Elsafi Mabrouk MH, Goetzke R, Wagner W. Epigenetic biomarkers to track differentiation of pluripotent stem cells. Stem Cell Rep. 2023;18(1):145\u201358.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"1877_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41408-023-00936-1","volume":"13","author":"M Vieri","year":"2023","unstructured":"Vieri M, Tharmapalan V, Kalmer M, Baumeister J, Nikolic M, Schnitker M, et al. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms. Blood Cancer J. 2023;13(1):164.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1877_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12915-020-00807-2","volume":"18","author":"Y Han","year":"2020","unstructured":"Han Y, Franzen J, Stiehl T, Gobs M, Kuo CC, Nikolic M, et al. New targeted approaches for epigenetic age predictions. BMC Biol. 2020;18(1):71.","journal-title":"BMC Biol"},{"issue":"10","key":"1877_CR26","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","volume":"14","author":"S Horvath","year":"2013","unstructured":"Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.","journal-title":"Genome Biol"},{"key":"1877_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2105-13-86","volume":"13","author":"EA Houseman","year":"2012","unstructured":"Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012;13:86.","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"1877_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","volume":"5","author":"S Alimam","year":"2021","unstructured":"Alimam S, Villiers W, Dillon R, Simpson M, Runglall M, Smith A, et al. Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5(4):1059\u201368.","journal-title":"Blood Adv"},{"issue":"9","key":"1877_CR29","first-page":"2551","volume":"108","author":"O Marin-Bejar","year":"2023","unstructured":"Marin-Bejar O, Romero-Moya D, Rodriguez-Ubreva J, Distefano M, Lessi F, Aretini P, et al. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. Haematologica. 2023;108(9):2551\u20137.","journal-title":"Haematologica"},{"issue":"1","key":"1877_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13148-021-01002-y","volume":"13","author":"M Cabezon","year":"2021","unstructured":"Cabezon M, Malinverni R, Bargay J, Xicoy B, Marce S, Garrido A, et al. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Clin Epigenetics. 2021;13(1):9.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1877_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23244","volume":"10","author":"G O'Brien","year":"2024","unstructured":"O\u2019Brien G, Cecotka A, Manola KN, Pagoni MN, Polanska J, Badie C. Epigenetic signature of ionizing radiation in therapy-related AML patients. Heliyon. 2024;10(1): e23244.","journal-title":"Heliyon"},{"issue":"23","key":"1877_CR32","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1038\/onc.2015.359","volume":"35","author":"HJ Ferreira","year":"2016","unstructured":"Ferreira HJ, Heyn H, Vizoso M, Moutinho C, Vidal E, Gomez A, et al. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia. Oncogene. 2016;35(23):3079\u201382.","journal-title":"Oncogene"},{"issue":"5","key":"1877_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1101\/gr.269233.120","volume":"31","author":"B Giacopelli","year":"2021","unstructured":"Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, et al. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Res. 2021;31(5):747\u201361.","journal-title":"Genome Res"},{"issue":"11","key":"1877_CR34","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/bloodadvances.2021005381","volume":"6","author":"G Yamato","year":"2022","unstructured":"Yamato G, Kawai T, Shiba N, Ikeda J, Hara Y, Ohki K, et al. Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia. Blood Adv. 2022;6(11):3207\u201319.","journal-title":"Blood Adv"},{"key":"1877_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13072-015-0035-3","volume":"8","author":"P Singmann","year":"2015","unstructured":"Singmann P, Shem-Tov D, Wahl S, Grallert H, Fiorito G, Shin SY, et al. Characterization of whole-genome autosomal differences of DNA methylation between men and women. Epigenetics Chromatin. 2015;8:43.","journal-title":"Epigenetics Chromatin"},{"key":"1877_CR36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1186\/s12864-015-2034-y","volume":"16","author":"P Yousefi","year":"2015","unstructured":"Yousefi P, Huen K, Dave V, Barcellos L, Eskenazi B, Holland N. Sex differences in DNA methylation assessed by 450 K BeadChip in newborns. BMC Genomics. 2015;16:911.","journal-title":"BMC Genomics"},{"issue":"1","key":"1877_CR37","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1038\/s41598-024-53240-8","volume":"14","author":"K Holl","year":"2024","unstructured":"Holl K, Chatain N, Krapp S, Baumeister J, Maie T, Schmitz S, et al. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms. Sci Rep. 2024;14(1):2810.","journal-title":"Sci Rep"},{"key":"1877_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00234","author":"I Plo","year":"2017","unstructured":"Plo I, Bellann\u00e9-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W. Genetic alterations of the thrombopoietin\/MPL\/JAK2 axis impacting megakaryopoiesis. Front Endocrinology. 2017. https:\/\/doi.org\/10.3389\/fendo.2017.00234.","journal-title":"Front Endocrinology"},{"issue":"6","key":"1877_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379.","journal-title":"Blood"},{"key":"1877_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/415024","volume":"2015","author":"C Desterke","year":"2015","unstructured":"Desterke C, Martinaud C, Ruzehaji N, Le Bousse-Kerdiles MC. Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. Mediators Inflamm. 2015;2015: 415024.","journal-title":"Mediators Inflamm"},{"issue":"3","key":"1877_CR41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-12-0735","volume":"73","author":"S Nischal","year":"2013","unstructured":"Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res. 2013;73(3):1076\u201385.","journal-title":"Cancer Res"},{"issue":"1","key":"1877_CR42","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1038\/s41598-017-07057-3","volume":"7","author":"HM Nielsen","year":"2017","unstructured":"Nielsen HM, Andersen CL, Westman M, Kristensen LS, Asmar F, Kruse TA, et al. Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. Sci Rep. 2017;7(1):6774.","journal-title":"Sci Rep"},{"issue":"9","key":"1877_CR43","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/jcmm.13095","volume":"21","author":"S McPherson","year":"2017","unstructured":"McPherson S, McMullin MF, Mills K. Epigenetics in myeloproliferative neoplasms. J Cell Mol Med. 2017;21(9):1660\u20137.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"1877_CR44","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/gb-2014-15-2-r31","volume":"15","author":"AE Jaffe","year":"2014","unstructured":"Jaffe AE, Irizarry RA. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 2014;15(2):R31.","journal-title":"Genome Biol"},{"issue":"5","key":"1877_CR45","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/clinchem\/hvac006","volume":"68","author":"S Sontag","year":"2022","unstructured":"Sontag S, Bocova L, Hubens WHG, N\u00fcchtern S, Schnitker M, Look T, et al. Toward clinical application of leukocyte counts based on targeted DNA methylation analysis. Clin Chem. 2022;68(5):646\u201356.","journal-title":"Clin Chem"},{"issue":"11","key":"1877_CR46","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/clinchem\/hvad143","volume":"69","author":"WHG Hubens","year":"2023","unstructured":"Hubens WHG, Maie T, Schnitker M, Bocova L, Puri D, Wessiepe M, et al. Targeted DNA methylation analysis facilitates leukocyte counts in dried blood samples. Clin Chem. 2023;69(11):1283\u201394.","journal-title":"Clin Chem"},{"key":"1877_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01002-y","author":"M Cabez\u00f3n","year":"2021","unstructured":"Cabez\u00f3n M, Malinverni R, Bargay J, Xicoy B, Marc\u00e9 S, Garrido A, et al. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Clin Epigenetics. 2021. https:\/\/doi.org\/10.1186\/s13148-021-01002-y.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1877_CR48","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/ijms24010633","volume":"24","author":"L Kalinkova","year":"2022","unstructured":"Kalinkova L, Sevcikova A, Stevurkova V, Fridrichova I, Ciernikova S. Targeting DNA methylation in leukemia, myelodysplastic syndrome, and lymphoma: a potential diagnostic, prognostic, and therapeutic tool. Int J Mol Sci. 2022;24(1):633.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1877_CR49","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1182\/blood-2009-01-200519","volume":"114","author":"ME Figueroa","year":"2009","unstructured":"Figueroa ME, Skrabanek L, Li YS, Jiemjit A, Fandy TE, Paietta E, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448\u201358.","journal-title":"Blood"},{"key":"1877_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.854797","volume":"10","author":"W Wagner","year":"2022","unstructured":"Wagner W. How to translate DNA methylation biomarkers Into clinical practice. Front Cell Dev Biol. 2022;10: 854797.","journal-title":"Front Cell Dev Biol"},{"key":"1877_CR51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2105-13-86","volume":"13","author":"EA Houseman","year":"2012","unstructured":"Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012;13:86.","journal-title":"BMC Bioinformatics"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01877-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T09:02:33Z","timestamp":1746262953000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01877-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01877-1","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All samples were obtained after informed and written consent in accordance with the Declaration of Helsinki and the research was specifically approved by the local ethics committee of RWTH Aachen University (EK 041\/15, EK 206\/09 and EK 127\/12).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"W.W. and V.T. are involved in the company Cygenia GmbH () that can provide service for epigenetic analysis to other scientists. Apart from this the authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}